Indivior Pharmaceuticals, Inc. Operating Income
Indivior Pharmaceuticals, Inc. (SUPN) reported Operating Income of $160.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was $160.00M, a 122.22% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was $137.00M, a 107.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was $81.00M, a 76.09% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was $43.00M, a 22.86% increase year-over-year.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was $262.00M, a 589.47% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was $38.00M.
- Indivior Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$152.00M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $160.00M 10-Q · filed 2026-08-03 | $297.00M 10-Q · filed 2026-08-03 | $378.00M derived: sum of 3 quarters · filed 2026-08-03 | $421.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $137.00M 10-Q · filed 2026-04-30 | $218.00M derived: sum of 2 quarters · filed 2026-04-30 | $261.00M derived: sum of 3 quarters · filed 2026-04-30 | $333.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $124.00M derived: sum of 2 quarters · filed 2026-02-26 | $196.00M derived: sum of 3 quarters · filed 2026-08-03 | $262.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $43.00M 10-Q · filed 2025-10-30 | $115.00M derived: sum of 2 quarters · filed 2026-08-03 | $181.00M 10-Q · filed 2025-10-30 | $227.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $72.00M 10-Q · filed 2026-08-03 | $138.00M 10-Q · filed 2026-08-03 | $184.00M derived: sum of 3 quarters · filed 2026-08-03 | $219.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $66.00M 10-Q · filed 2026-04-30 | $112.00M derived: sum of 2 quarters · filed 2026-04-30 | $147.00M derived: sum of 3 quarters · filed 2026-04-30 | $29.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $46.00M 10-K · filed 2026-02-26 | $81.00M derived: sum of 2 quarters · filed 2026-02-26 | -$37.00M derived: sum of 3 quarters · filed 2026-02-26 | $38.00M 10-K · filed 2026-02-26 | $32.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $35.00M 10-K · filed 2026-02-26 | -$83.00M derived: sum of 2 quarters · filed 2026-02-26 | -$8.00M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$118.00M 10-K · filed 2026-02-26 | -$43.00M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $75.00M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | -$152.00M 10-K · filed 2026-02-26 | -$156.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$77.00M 10-Q · filed 2025-10-30 | -$81.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |